Asepsis Announces the Grant of U.S. Patent 10,857,299 for the Multi-Dose Safe-2-Dose® Syringe

Asepsis Medical Technologies® is proud to introduce the latest addition to the Calibrated Drug Delivery™ (CCD) platform, the Multi-Dose Safe-2-Dose® syringe.

The Multi-Dose Safe-2-Dose® syringe provides the ability to dose medication according to at least two patient characteristic-based dosing instructions.  Medication specific dosing indicia allows for loading, maximum or maintenance dosing according to patient characteristics such as weight or BSA.  Available oral and parenteral Multi-Dose Safe-2-Dose® syringe versions are designed to enhance patient outcome and medication efficacy by providing higher precision adherence to optimal clinical dosing.  In addition, the CDD platform enhances convenience and safety by providing health care professionals with intuitive indicia that simplifies medication preparation and administration procedures.

Asepsis Announces the Safe-2-Dose™ Integrated Dosing Container

Asepsis announces the patent pending Safe-2-Dose™, the next generation liquid medication dispenser. The caregiver need only unlock the device and squeeze the bottle to obtain the correct amount of medication to the unique multi-indicia display for either patient characteristic or drug dose. The Safe-2-Dose’s calibrated indicia and integrated dosing device enhances overall safety through user convenience and patient dosing accuracy.   

Asepsis Announces Australian Patent Acceptance No. 2018232988 for its Multi-Indicia Infants’ and Children’s Oral Medication Dosing Applicator Comprising a Medication Paired Keyed End.

Asepsis Medical Technologies announces the Australian Patent Acceptance No.  2018232988 for a suction and/or pressure inducing oral medication dosing applicator.  The applicator comprising multiple dosing mode indicia, such as dose to patient weight, age or other characteristic; is also designed with a keyed end to provide a paired connection with a container. This correlated safety pairing inhibits the separate use of the calibrated dosing device and medication. This design feature further enhances patient safety during the preparation and administration of children’s and infants’ oral medication.

 

Asepsis announces the USPTO Notice of Allowance for its second Patent Application for the Safe-T-Fuse™ specialty drug infusion system.

Asepsis Medical Technologies announces the USPTO issuance of Patent Application Number 15/255,725 for its Safe-T-Fusedrug infusion system. The Safe-T-Fuse is an industry unique infusion container that allows the contents of a standard reconstitutable vial to be quickly introduced to its integrated reservoir without any additional components. By design, the device allows a user to precisely control the volume and duration of the medication’s reconstitution and the subsequent closed system metered transfer to its integrated infusion reservoir.

Continue reading Safe-T-Fuse

 

  • The Safe-T-Fuse™ is a trademark of Asepsis Medical Technologies, LLC., and covered by two or more patents, including; U.S. Patent 9,433,726 and Patent Application Number 15/255,725, as well as Patents Pending.